 
 
V IS IONCARE RESEARCH  
 
 
 
 
 
 
 
PROTOCOL 
 
VERS ION 1 
 
 
 
MULT I- CENTER CROSS- OVER EVALUAT ION  
OF AVA IRA V ITAL ITY™ S IL ICONE HYDROGEL  
CONTACT LENS AND TWO HYDROGEL  
LENSES IN  DA ILY WEAR 
 
 
 
SPONSOR :  Coope rV is ion  Inc .  
 
STUDY NUMBER :  AVAR- 402   (EX - MKTG- 103 )  
 
DATE:  Ma rch 22 , 2019 
 
PROPOSED START DATE : Ap r i l2019  
 
AUTHORS :  G raeme Young 
K r is t ine Ro s l in 
 
 
 
   
  
  
 
   
 
 
   
    
    
 
  
   
     
      
 
 
 
 
 
 
 
PRO AVAR- 402 Ve r s ion 1 22MAR2019 Page 1 o f48 
V I  S I  O N C A R E    R E S E A R C H 
Page 4 o f  48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
Mu l t i- cen ter  c ross- over  evalu at ion  o f Avai r a Vi t al i t y™ si l i cone hydr ogel  cont act  l ens and t wo  
hydr ogel  l enses in  dai l y wear  
 
 AVAR- 402 ( EX- MKTG- 103)  
 
TABLE OF CONTENTS  
  
Page 
 
PERSONNEL AND FACI LI TI ES  
6 
 
1  
IN TRODUCTION   
9 
 
2  
STUDY OBJECTI VES  
9 
 
3  
STUDY DESIGN  & RATION ALE  
9 
3 .1 S tud y Design  9 
3 .2 S tud y Ra t iona le 9 
3 .3 Pr i mar y  Ou tcome Hy po thes is 9 
3 .4 Secondar y  Ou tcome Hy po theses 10 
3 .5 Saf e ty Hy po the s is 10 
3 .6 Masking  10 
3 .7 Randomi z a t ion 10 
 
4  
STUDY POPULATION   
11 
4 .1 Number  o f S i te s 11 
4 .2 In v est iga to r  Recr u i tmen t 11 
4 .3 Number  o f Subj ect s  11 
4 .4 In c lu s ion  Cr i te r ia  11 
4 .5 Excl usion  Cr i te r ia  12 
4 .6 Subj ect  Iden t i f i ca t ion 12 
4 .7 S tud y Wi thd r awa l Cr i te r ia  13 
4 .8 Subj ect  Rep lacemen t 13 
4 .9 Med ica t ions/ T rea tmen ts Per mi t ted  and No t Per mi t ted  Dur ing  the  S tud y 13 
4 .10 Pr ocedur es f o r Mon i tor i ng Subj ect  Adher ence 13 
 
5  
MATER IALS  
14 
5 .1 S tud y Lenses 14 
5 .2 Lens Car e Pr oduct s  and Othe r  S tud y Pr oduct s  14 
5 .3 Pr oduct  Accoun tabi l i t y  14 
5 .4 Lens Wear ing  Schedu le 15 
5 .5 Po ten t ia l Ri sks and Benef i t s  f o r Human Subj ect s  15 
5 .6 S tud y Documen ts and eCRFs 15 
 
6  
TREATMENT  
15 
6 .1 S tud y Pr oduct  For mu la t ion s 15 
6 .2 Lens Admin i st r a t ion 16 
 
7  
METHODS AND ASSESSMENTS  
16 
7 .1 Subj ect  Recr u i tmen t 16 
7 .2 S tud y V isi t s  16 
7 .3 C l in ical  Var iab l es  27 
7 .4 Subj ect  D iscon t inuat ion  28 
7 .5 Unschedu led Vi si t s  29 
7 .6 S i te T ra in ing and V is i t s  29 
 
8  
ADVERSE EVENTS  
29 
8 .1 Adv er se Ev en t Ca tegor i z a t ion 30 
8 .2 Adv er se Ev en t Repor t ing  31 
8 .3 Adv er se Ev en t Documen ta t ion 31 
V I  S I  O N C A R E    R E S E A R C H 
Page 5 o f  48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
8 .4 Adv er se Ev en t Fo l low- up 32 
8 .5 S tud y Comp le t ion 32 
9 DATA MANAGEMENT 32 
9 .1 E lect r on ic Case Repor t  For ms/Da ta  Co l lect ion  32 
9 .2 Da ta Qual i t y  Assur ance 33 
9 .3 Da ta En tr y  and S tor age 33 
10 SAMPLE SI ZE AND STATI STIC AL METHODS 33 
10 .1 Samp le S iz e Ra t iona le 33 
10 .2 End- po in t s 33 
10 .3 S ta t ist i ca l Cons ide r a t ion s 34 
10 .4 Ana ly sis  Popula t ion  34 
10 .5 Descr ip t i v e S ta t ist i c s  34 
10 .6 Da ta Poo l ing 34 
10 .7 Pr i mar y  S ta t ist i cal  Ana l y si s 34 
10 .8 Secondar y  S ta t ist i cal  Ana l y si s 35 
10 .9 Add i t iona l S tat i st i ca l Ana ly si s  35 
10 .10 In te r im  Ana ly sis  35 
11 GENERAL  STUDY MANAGEMENT 35 
11 .1 Re lev an t S tandar ds 35 
11 .2 E th ics Rev iew  35 
11 .3 Pr o toco l Dev ia t ion s  35 
11 .4 Pr ema tur e Ter mina t ion  o f  the S tud y 36 
11 .5 Sour ce Documen ta t ion 36 
11 .6 Mon i tor ing  36 
11 .7 Aud i t s 37 
11 .8 Recor ds Re ten t ion 37 
11 .9 Conf iden t i al i t y  and Publ i ca t ion 37 
12 REFERENCES 39 
APPEND IX A G radi ng Scal es & Measur ement  I nst r uct i ons 40 
V I  S I  O N C A R E    R E S E A R C H 
Page 6 o f  48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
Mu l t i- cen ter  c ross- over  evalu at ion  o f Avai r a Vi t al i t y™ si l i cone hydr ogel  cont act  l ens and t wo  
hydr ogel  l enses in  dai l y wear  
 
AVAR- 402 ( EX- MKTG- 103)  
PERSONNEL AND FAC ILI TI ES 
 
SPONSOR :   
    
  
   
 
 
 
     
    
  
 
 
      
  
 
 
         
 
 
      
  
  
 
   
 
    
    
 
    
  
     
  
 
 
    
   
    
  
 
 
    
V I  S I  O N C A R E    R E S E A R C H 
Page 9 o f  48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
1 IN TRODUCTI ON 
 
There  has been a t r end over  t he la st  20 y ears  of  mov i ng f r om hy dr ogel  to  s i l i cone hy dr ogel  
cont act  l enses.1 I n 2018,  t hr ee- quar t ers  ( 76% ) of  pr escr ibe d sof t  l enses i n t he US were  si l i cone  
hy dr ogel  l enses and t h is t r end i s l i kel y  t o cont in ue.2   Wi th  exi st i ng  hy dr ogel   user s,  an  
i mped iment  to  r ef i t t i ng to  si l i cone hy dr ogel s i s t he concern  t hat  t he comf or t  and wet t i ng  
per f or mance may  be i nf er io r ,  t hus,  mi t i gat in g t he obv i ous benef i t s  of  i mpr ov ed oxy gen  
av ai l abi l i t y .  
 
The Av ai r a® V it al i t y ™ ( f anf i l c on A)  sof t  cont act  l ens i s a si l i cone hy dr ogel  len s in di cat ed f or  t he  
cor r ect i on of  my opi a and hy per opi a.  Th is was la unched r ecent l y  (F DA 510k appr ov al :  2016)  
and has,  t her ef or e,  been t he subj ect  of  f ew cl i n ical  st ud ies.  The 510k appl i cat i on r epor t ed a  
3- month  compar at i v e c l i ni cal  st udy  i nv ol v i ng 90 subj ect s  and i n whi ch t he l ens was f ound to  be  
subst ant ia l l y  equi v al ent  to  t he cont r ol  len s ( st enf i l con A) .3 
 
Th is st udy  a ims to  si mu late  t he swi t chin g of  hy dr ogel  len s wear ers  t o Av ai ra  Vi t a li t y  si l i cone  
hy dr ogel  l enses.  Two of  t he most  commonl y  used hy dr ogel s are  Acuv ue 2 ( Johnson &  
Johnson)  and Bi omed ics 55 Pr emie r  (C ooper V ision ) .  Acuv ue 2 i s a wel l - est abl i shed hy dr ogel  
len s and has been t est ed i n a wid e r ange of  c l i ni cal  st udi es .4- 7 Bi omed ics 55 Pr emie r  i s an  
i mpr ov ed v er s i on of  t he Bi omed ics  55 l ens wh ich has a lso been t est ed i n a number  of  cl i n ical  
st ud ies.8- 12 
 
The pur pose of  t he pr oposed st udy ,  t her ef or e,  i s to  ev al uate  t he c l i ni cal  per f or manc e of  Av ai ra  
V it al i t y  i n compar i son wi th  hy dr ogel  l enses i n subj ect s  swi t ched f r om hy dr ogel  to  si l i cone  
hy dr ogel  cont act  l enses.  
 
 
2 STUDY OBJECTI VES 
 
The a im of  t h is st udy  wi l l  be to  ev alua t e t he compar at i v e c l i ni cal  per f or mance of  t he Av ai ra  
V it al i t y ™ si l i cone hy dr ogel  l ens used i n dai l y  wear  and to  compare  t h is wi th  compet i t iv e  
hy dr ogel  l ens pr oduct s ,  Bi omed ics 55 Pr emie r  and Acuv ue 2.  
 
 
3 STUDY DESI GN & RATI ONALE 
 
 
3 .1 St udy  Desi gn 
 
An appr ox.  100- 120 subj ect ,  8- week,  sing l e- mas ked,  b i lat er al ,  t wo- par t ,  cr oss- ov er  ev a luat i on  
of  hy dr ogel  and s i l i cone hy dr ogel  l enses i n dai l y  wear .  Lenses wi l l  be r ep laced e it her  on a  
2- weekl y  or  4- weekl y  basi s,  dependin g on cont r ol  l ens gr oup.  
 
 
3 .2 St udy  Rat i ona le 
 
In  or der  to  compare  t he comf or t ,  wet t i ng and deposi t i on,  i t  i s necessar y  to  make a wi t h in- subj ect  
compar i son.  A cr oss- ov er  st udy  i s t her ef ore  seen as t he most  appr opr ia t e compar i son.  
Swi t chi ng f r om hy dr ogel  to  si l i cone hy dr ogel  len s si mu lat es t he common sequence of  ev ent s  i n  
cur r ent  cl i n ical  pr act i ce.  Howev er ,  t h is does not  al l ow a r andomi z ed compar i son and may  be  
subj ect  to  sequence bi as.  
 
 
3 .3 Pr i mar y  Out come Hy pot hesi s 
 
Subj ect iv e com for t  r epor t ed at  t he v i si t  wi l l  be bet t er  wi t h Av a ira  V it al i t y  t han t he cont r ol  cont act  
len ses at  t he f in al  vi si t .  
V I  S I  O N C A R E    R E S E A R C H 
Page 10 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
3 .4 Secondar y  Out come Hy po theses 
 
i .  Av er age wear i ng t i me wi l l  be lo nger  wi t h Av a ira  V it al i t y  t han t he cont r ol  cont act  l enses  
at  t he f in al  vi si t .  
 
i i .  Com for t ab le wear in g t i me wi l l  be l onger  wi th  Av a ira  V it al i t y  t han t he cont r ol  cont act  
len ses at  t he f in al  vi si t .  
 
i i i .  Pr e- l ens t ear  f i l m qua l it y  wi l l  be bet t er  wi th  Av a ira  V it al i t y  t han t he cont r ol  cont act  l enses  
at  t he f in al  vi si t .  
 
i v .  Fi l m deposi t s  wi l l  be bet t er  wi th  Av a ira  Vi t al i t y  t han th e cont r ol  cont act  len ses at  t he  
f ina l  v i s i t .  
 
v .  Wh ite  spot  deposi t s  wi l l  be f ewer  wi t h Av ai ra  Vi t al i t y  t han t he cont r ol  cont act  len ses at  
t he f in al  v i s it .  
 
v i .  Ov er al l  len s f i t  accept ance wi l l  be bet t er  wi t h Av a ira  V it al i t y  t han t he cont r ol  cont act  
len ses at  t he f in al  vi si t .  
 
 
3 .5 Saf et y  Hy pot hesi s 
 
The st udy  len ses are  FDA appr ov ed,  t her ef or e,  no saf et y  end poin t s  ar e r equi r ed.  
 
Howev er ,  i n or der  to  ensure  t he cont in ued saf et y  of  t he subj ect s  i n t he t r i a l,  s l i t  l amp f ind ing s  
wi l l  be assessed at  al l  v i si t s and t he spect acl e r ef r act i on and VA wi l l  be col le ct ed at  t he st ar t  
and end of  t he st udy .  Adv er se ev ent s  wi l l  al so be r ecor ded and mon it or ed f o ll owi ng t he  
pr ocedur es l i st ed i n Sect i on 8.  
 
 
3 .6 Maskin g 
 
Subj ect s  wi l l  be mas ked to  len s t y pe.  When len ses are  d ispensed,  t he bl i st er  packs wi l l  be  
opened out  of  sigh t  of  t he subj ect .  I nv est iga t ors  wi l l  be unmas ked.  
 
 
3 .7 Randomi z at i on 
 
Subj ect s  wi l l  be r andoml y  al lo cat ed to  one of  t he t wo  cont r ol  gr oups .  The or der  of  wear  of  t he  
t est  and cont r ol  len ses wi l l  not  be r andomi z ed.  A r andom number  gener at or  ( M icr osof t  Exce l)  
usin g a blo ckin g met hod and st r at i f i ed by  si t e wi l l  det er min e t he r andomi z at io n of  cont r ol  l enses  
to  subj ect s,  wh ich wi l l  t hen be in cor por at ed in to  t he Randomi z at i on Log.  ID  numbers  wi l l  be  
assign ed consecut i v el y  t o ma int a in r andomi z at i on.  
 
The r andomi z ed assi gnment  of  subj ect s  wi l l  be per f or med at  t he f i r st  assess ment .  The  
f o l lowin g must  hav e occur r ed pr i or  to  r andomi z at i on:  
 
• I nf or med consent  has been obt ai ned 
• Subj ect  meet s  al l  t he i nclu sio n /  exclu s i on cr i t er i a 
• Subj ect  hi st or y  and basel i ne in f or mat i on hav e been col le ct ed 
V I  S I  O N C A R E    R E S E A R C H 
Page 11 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
4 STUDY POPULATI ON 
 
 
4 .1 Number  of  S it es  
 
Appr oxi mat el y  si x si t es l ocat ed i n t he US,  each r ecr u it i ng appr oxi mat el y  22 subj ect s .  
I nv est i gat ors  wi l l  be cont act  l ens pr act i t i oners  wi th  at  l east  3 y ears  post - r egi st r at i on exper i ence  
of  cont act  l ens f i t t i ng.  
 
 
4 .2 I nv est i gat or  Recr u it ment  
 
I nv est i gat i onal  s it es wi l l  be i dent i f ie d by  V is i oncare  Resear ch.  The i nv est i gat ors  wi l l  be r equi r ed  
to  f u lf i l  t he f ol l owin g cr i t er i a:  
 
• Appr opr i at el y  l i censed ey e care  pr act i t io ner  or  cont act  len s opt i cia n 
• At  l east  t hr ee y ears  post - r eg ist r at i on cont act  len s f i t t i ng exper i ence.  
• I n- of f i ce ema i l.  
• Wi l l ingne ss to  f ol l ow t he st udy  pr ot ocol  and to  co- oper ate  wi th  t he st udy  mon it or s.  
• Exper i enced i nv est ig at ors  t r a ined i n Good Cl i ni cal  Pr act i ce (GC P)  and t he st udy  
pr ot ocol  pr i or  to  commencin g t he st udy .  
• Comput ers  av ai l abl e to  comp lete  CRFs usi ng ele ct r on ic data  capt ure  ( EDC ) . 
 
Al l  of  t he  i nv est i gat i onal  si t es wi l l  be t r ai ned and  ev al uat ed by  on- l i ne t r ai ni ng modul es  bef ore  
enr ol l i ng subj ect s.  
 
Th is cl in i cal  st udy  i s desi gned to  be i n conf or mance wi t h t he et h ical  pr in ci ple s i n t he Dec l ar at i on  
of  He lsin ki ,  wi th  t he I CH gui del ine s f or  GCP and al l  appl i cabl e lo cal  r egul at i ons.  
 
 
4 .3 Number  of  Subj ect s  
 
Appr oxi mat el y  100- 120 hab it ual  sof t  cont act  l ens wear ers  wi l l  be enr ol l ed i n t he st udy  acr oss  
a ll  si t es;  appr oxi mat el y  50- 60 subj ect s  wi l l  use each cont r ol  len s,  Bi omed ics 55 Pr emie r  or  
Acuv ue 2,  bef ore  usin g t he t est  l ens,  Av ai ra  V it al i t y .  
 
Each subj ect  wi l l  be r equi r ed to  at t end up t o f i v e schedule d st udy  v i si t s  ov er  a per io d of  
appr oxi mat el y  8- weeks.  
 
The st udy  popul at i on has been chosen t o r epr esent  t he r ange of  pat i ent s  t hat  may  use t hese  
cont act  l ens t y pes.  Subj ect s  wi l l  be adapt ed sof t  cont act  len s wear ers  and wi l l  be r ecr u it ed f r om  
t he si t es’  exi st i ng pat i ent  dat abase or  v i a I RB appr oved r ecr ui t ment  mat er ia l .  The enr ol ment  
per i od f or  t he st udy  i s expect ed to  la st  appr oxi mat el y  5 weeks.  
 
 
4 .4 I nclu s i on Cr i t er i a 
 
Al l  subj ect s  must  sat i sf y  t he f o l lowi ng cond it i ons pr io r  to  i nclu s i on i n t he st udy :  
 
i .  Be a cur r ent l y  adapt ed sof t  cont act  l ens wear er  ( >1 month  of  l ens wear ) .  
 
i i .  Be at  l east  18 y ears  of  age.  
 
i i i .  Ref r act i v e ast i gmat i s m <1. 00D i n both  ey es.  
 
i v .  Have cl ear  cor neas and be f r ee of  any  ant er i or  segment  d isor der s.  
 
v .  Be cor r ect abl e t hr ough spher ocy l i ndr i cal  r ef r act i on t o 20/ 25 or  bet t er  i n each ey e.  
 
v i .  Cont act  l ens sphere  r equi r ement  bet ween - 1. 00D and - 6. 00D ( in c l usi v e) .  
V I  S I  O N C A R E    R E S E A R C H 
Page 12 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
v i i .  Requi re  v i sual  cor r ect i on i n both  ey es ( monov i s i on al l owed,  no monof i t ) .  
 
v i i i .  Have nor mal  ey es  w i th  no ev id ence of  abnor ma l it y  or  d isease.  For  t he pur poses  of  t h is  
st udy  a nor mal  ey e i s def i ned as one hav i ng:  
a . No ambl y opi a 
b . No st r ab ismus  
c .  No ev i dence of  l i d abnor ma l it y  or  in f ect i on 
d . No conj unct i v al  abnor ma l it y  or  in f ect i on t hat  woul d con tr a indi cate  cont act  l ens wear  
e . No cl i n ical l y  s i gni f i cant  s l i t  l amp f ind i ngs ( i . e.  cor neal  st a inin g,  st r omal  edema,  
st a ining ,  scar r ing ,  v ascula r i z at io n,  i nf i l t r at es or  abnor mal  opaci t ie s)  
f .  No ot her  act iv e ocula r  di sease.  
i x .                 .  
 
x .  Wi l l in g to  compl y  wi t h t he wear  and st udy  v i si t  schedul e.  
 
 
4 .5 Exclu si on C ri t er i a 
 
Any  of  t he f ol l owi ng wi l l  r ender  a subj ect  i nel ig i bl e f or  i nclu si on:  
 
i .  Usin g Cooper Vi si on Av ai ra  V it al i t y ,  J&J Acuv ue 2 or  Cooper V is i on Bi omed ics 55.  
 
i i .  Requi re  t or i c or  mu lt i f ocal  cont act  len ses.  
 
i i i .  Pr ev i ous ly  shown a sensi t iv i t y  to  any  of  t he st udy  sol ut i on component s.  
 
i v .  Any  sy st emi c or  ocul ar  d isease or  al l er g ies af f ect i ng ocu lar  heal t h.  
 
v .  Usin g sy st emi c or  t op ical  med icat i ons t hat  wi l l  i n  the i nv est i gat or ’ s opi nio n  af f ect  ocu lar  
phy sio l ogy  or  len s per f or mance.  
 
v i .  Cl i n ical l y  si gn if i cant  ( >G rade 3)  cor neal  st ai ni ng,  cor neal  st r omal  edema,  cor neal  
v ascul ar i z at ion ,  t ar sal  abnor ma l it i es,  bulba r  hy per emia ,  l i mbal  hy per emia ,  or  any  ot her  
abnor ma l it y  of  t he cor nea t hat  woul d cont r a ind icat e cont act  l ens wear .  
 
v i i .  Any  cor neal  in f i l t r at es or  any  cor neal  scar r in g or  neov ascul ar i z at io n wi t hi n t he cent r al  
5mm of  t he cor nea.  
 
v i i i .  Ker at oconus or  ot her  cor neal  i r r egula r i t y .  
 
i x .  Aphaki a or  ambl y op ia.  
 
x .  Have under gone cor neal  r e fr act i v e sur ger y  or  any  ante r io r  segment  sur ger y .  
 
x i .  Abnor mal  la cr i mal  secr et i ons.  
 
x i i .  Has di abet es.  
 
x i i i .  Known/ r epor t ed in f ect i ous d isease ( e. g. ,  hepat i t i s,  t uber culo si s)  or  an  
i mmunosuppr essi v e d isease ( e. g. ,  HI V) .  
 
x i v .  Hi st or y  of  chr on ic ey e d isease ( e. g.  gl aucoma) .  
 
xv .  Pr egnant  or  l act at i ng or  pl anni ng a pr egnancy  at  t he t i me of  enr o lment .  
 
xv i .  Par t i cipa t i on i n any  concur r ent  c l i ni cal  t r i al  or  i n l ast  30 day s.  
 
 
4 .6 Subj ect  I dent i f i cat i on 
 
Subj ect s  w i l l  be i dent i f ie d by  a  f our - d igi t  code made up of  t he si te  number  and t hei r  enr o lment  
number .  
 
The enr o lment  ID  must  be assign ed t o t he subj ect s  sequent i al l y  and i n ascendin g or der  f or  
each s i t e.  Ther ef or e,  t he f i r st  subj ect  at  S it e 1 wi l l  be al lo cat ed I D 01/ 01,  t he second subj ect  wi l l  
be 01/ 02 and so on.  Subj ect  id ent i f i cat i on i s r ecor ded i n t he Enr ol ment  l og and cannot  be used  
more  t han once.  
V I  S I  O N C A R E    R E S E A R C H 
Page 13 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
4 .7 St udy  Wi t hdr awal  C ri t er i a 
 
I f  dur in g t he st udy  i t  becomes ev i dent  to  ei t her  t he sponsor  (C ooper V is i on)  or  V ision care  
Resear ch t hat  t he st udy  cont act  l enses pose a t hr eat  to  subj ect  wel l - being ,  t he st udy  wi l l  be  
t er mina t ed and t he I nst i t ut i onal  Rev i ew Board  ( I RB)  wi l l  be adv i sed of  t he r eason f or  
t er mina t i on.  
 
 
4 .8 Subj ect  Repla cement  
 
Subj ect s  t hat  are  d iscont i nued f r om t he st udy  wi l l  not  be r epla ced.  
 
 
4 .9 Medi cat i ons/ Tr eat ment s  Per mi t t ed and Not  Per mi t t ed Dur i ng t he St udy  
 
Pr eser v at i v e f r ee r ewet t in g/ com for t  dr ops may  be used i n t hi s st udy ,  as needed,  to  lub r i cate  
and r ewet  len ses,  i f  agr eed by  t he i nv est iga t or .  
 
The use of  t opi cal  ocul ar  med icat i ons i s cont r ain di cat ed at  al l  t i mes dur in g t hi s st udy  unle ss  
pr escr ibe d as par t  of  a t r eat ment  f or  an adv er se ev en t.  The use of  any  ocul ar  med icat i ons to  
t r eat  condi t i ons t hat  ar i se wi l l  r equi re  t empor ar y  suspensi on of  l ens wear ,  an adv er se ev ent  
r epor t ,  and ev a luat i on of  t he subj ect  f or  d iscont in uat i on f r om t he st udy .  
 
For  any  adv er se ev ent  where  l ens wear  i s suspended,  an unschedul ed f o ll ow- up ev alua t i on of  
t he subj ect  must  be per f or med bef ore  al l owin g t he subj ect  to  r et ur n to  len s wear .  Subj ect s  may  
not  r et urn  t o l ens wear  unt i l  al l  t opi cal  ocul ar  medi c at i ons hav e been d iscont in ued and a  
document ed exam has v er i f ie d t he r esol ut i on of  t he adv er se ev ent .  
 
4. 9.1  Concomi t ant  Medi cat i ons 
 
Changes i n concomi t ant  med icat i ons f r om t hose r ecor ded at  t he i n it i al  v i si t  shoul d be i nd icat ed  
on t he f o ll ow- up v i si t  f or ms by  checkin g ‘ Yes’  on t he concomi t ant  med icat i on quest i on and  
r ecor d ing t he change on th e appr opr i ate  EDC f or ms.  
 
 
4. 10 Pr ocedur es f or  Moni t or i ng Subj ect  Adher ence 
 
To t r ac k comp l iance,  subj ect s  wi l l  be asked at  each f ol l ow- up v i si t  about  t hei r  av er age cont act  
len s wear i ng t i mes  ( t y p ical  in ser t i on and r emov al  t i mes)  and av er age number  of  day s l enses  
are  worn  per  week.  
V I  S I  O N C A R E    R E S E A R C H 
Page 15 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
St udy  s it es wi l l  not  be r equi r ed to  r et ai n any  packag ing f r om used len ses.  
 
St udy  pr oduct  account abi l i t y  wi l l  be checked by  t he st udy  mon it or  ( assi gned by  t he sponsor  or  
VCR ) dur i ng si t e mon it or i ng.  Al l  unused l enses,  r et ur ned f r om subj ect s  or  nev er  d ispensed t o  
t he st udy  subj ect s,  must  be av ai l abl e t o t he st udy  moni t or  f or  v er i f i cat i on of  l ens account abi l i t y  
at  t he comp let i on of  t he st udy .  Any  di scr epanc i es i n st udy  l ens account abi l i t y  must  be expl ai ned  
by  t he i nv est i gat or .  Af t er  t he st udy  moni t or  has v er i f ie d pr oduct  account abi l i t y ,  any  unused  
mat er ia l s wi l l  be r et ur ned to  VCR or  to  t he sponsor  unl ess t he i nv est i gat or  i s ot her wi se di r ect ed  
by  t he VCR . Al l  pr oduct  r et ur ned to  VCR or  sponsor  wi l l  be document ed on t he Lens  
Account abi l i t y  For m.  
 
 
5 .4 Lens Wear in g Schedul e 
 
The subj ect  wi l l  be in st r uct ed to  wear  t he l enses on dai l y  wear  basi s,  f or  a min i mum of  8 hours  
a day ,  6 day s per  week and pr ef er abl y  7 day s per  week.  
 
 
5 .5 Pot ent i al  Ri sks and Benef i t s f or  Human Subj ect s  
 
Pot ent i al  Ri sks and benef i t s  f or  human subj ect s  wear i ng cont act  l enses are  summar i z ed i n t he  
I nf or med Consent  document  ( separ at e documen t) .  
 
 
5 .6 St udy  Documen ts and eCRFs 
 
The f o l lowi ng f or ms wi l l  be comp let ed where  appr opr i at e:  
 
eCRFs:  
• Basel i ne f or ms ( in clud i ng el ig i bi l i t y  checkl i st )  
• Tr ia l  Fi t  /  Di spensi ng f or m 
• Fo ll ow- up f or ms ( in clud i ng Unschedule d Vi si t )  
• Adv er se Ev ent  f or ms  
• St udy  Exi t  f or ms  
• Pr ot ocol  Dev ia t io n 
• Dev i ce Def i c i ency  
• Concomi t ant  med icat i on 
• Medi cal  Hi st or y  
 
Addi t i onal  For ms  
• St at ement  of  I nf or med Consent  
• Par t i cip ant  I nf or mat i on Sheet  
• S it e Respons i bi l i t y  Log 
• Enr ol ment  Log 
• Par t i cip ant  I nf or mat i on Gui de 
• Lens Di spens i ng Form  
• Lens Account abi l i t y  Form  
• Sour ce Document  Record  Label  
 
 
6 TREATMENT 
 
 
6 .1 St udy  Pr oduct  For mu lat i ons 
 
The t est  l enses wi l l  be shi pped i n bl i st er  packs cont a ini ng a buf f er ed sal in e packagin g so lut i on.  
The la bel l i ng of  l enses and packag ing wi l l  be t he st andard  packag ing whi ch wi l l  i nd icat e l ens  
power ,  base cur v e,  d iamet er ,  lo t  number  and exp ir at i on dat e.  
V I  S I  O N C A R E    R E S E A R C H 
Page 16 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
6 .2 Lens Admin i st r at i on 
 
Lenses wi l l  be used on a 2- weekl y  or  4- weekl y  dai l y  wear  basi s dependi ng on cont r ol  len s  
gr oup,  i . e.  len ses worn  dur i ng t he day ,  r emov ed at  nig ht  and cl eaned and st or ed wi th  Opt i - F ree  
Pur eMo ist  mu lt i pur pose sol ut i on.  
 
In  t he ev ent  of  len s lo ss or  damage,  r epl acement  le ns( es)  wi l l  be i ssued at  an unschedul ed  
v i s i t .  
 
 
7 METHODS AND ASSESSMENTS 
 
 
7 .1 Subj ect  Recr u it ment  
 
Recr u it ment  mat er ia l s ( adv er t s,  l et t er s,  et c. )  must  be appr ov ed by  t he I nst i t ut i onal  Rev i ew  
Board  ( I RB) .  I f  r equest ed,  VCR wi l l  pr ovi de an adv er t i sement  and l et t er  f or  r ecr u it ment  
pur poses.  Any  changes t o t hese must  be submi t t ed back to  t he IRB  v i a VCR . 
 
The pr ocedur es  l i st ed bel ow wi l l  be conduct ed on al l  subj ect s.  Var ia ble s must  be co ll ect ed i n  
t he or der  t hey  are  l i st ed on t he eCRF . 
 
To par t i cipa t e i n t h is c l i ni cal  st udy ,  t he I nv est ig at or  wi l l  expla i n t he St at ement  of  I nf or med  
Consent  to  t he subj ect ,  ensure  each subj ect  under st ands t he subj ect  in st r uct ion s  and det er min e  
subj ect  el ig i bi l i t y .  
 
The I nv est ig at or  i s r equi r ed to  answer  any  quest i ons t he subj ect  has concer ni ng t he st udy  or  
t he in f or mat i on cont ain ed i n t he St at ement  of  I nf or med Consent  and Pat i ent  I nf or mat i on Sheet .  
 
A subj ect  i s consi der ed enr o l led when he or  she s i gns t he St at ement  of  I nf or med Consent .  
O ther  st udy - r e lat ed act i v i t i es may  not  be under t aken pr io r  to  obt a ini ng i nf or med consent .  
 
Al l  subj ect s  enr ol l ed shoul d be account ed f or ,  ev en i f  t hey  are  not  d ispensed l enses or  st udy  
pr oduct .  A sig ned St at ement  of  I nf or med Consent  const i t ut es enr ol ment .  Af t er  enr o lment ,  a  
subj ect  i s conside r ed act i ve and shoul d be account ed f or  at  ev er y  v i s i t  unt i l  t he comp let i on of  
or  d iscont i nuat io n f r om t he st udy .  
 
Each si t e wi l l  be expect ed t o enr ol l  appr oxi mat el y  22 subj ect s.  
 
 
7 .2 St udy  V isi t s  
 
7 .2 .1 V isi t  Schedul e 
 
There  wi l l  be a maxi mum of  f i v e schedul ed v i s i t s depend ing on t he l ens t y pe:  
 
B iomed ics 55 Pr em ier  ( Con tr o l A)  
 
V isi t  1:  Basel i ne /  Tr ia l  Fi t  /  Cont r ol  A Di spensin g 
V isi t  2:  2- week Fo l low Up ( 14 day s - 1/ +3 day s f r om d ispens i ng)  
V isi t  3:  4- week Fo l low Up and di s pense Test  Lens ( 28 day s - 1/+3  day s f r om  
Cont r ol  Lens di spens i ng)  
V isi t  4:  6- week Fo l low Up ( 14 day s - 1/ +3 day s f r om Test  Lens d ispensing )  
V isi t  5:  8- week Fol l ow- up and Exi t  ( 28 day s - 1/ +3 day s f r om Test  Lens di spensing )  
 
Acuvue 2 (Con t r o l B ) 
 
V isi t  1:  Basel i ne /  Tr ia l  Fi t  /  Cont r ol  B Di spensin g 
V I  S I  O N C A R E    R E S E A R C H 
Page 29 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
In  t he ev ent  of  d iscont i nuat i on,  t he St udy  Ex i t  eCRF must  be comp let ed and t he st udy  exi t  dat e  
r ecor ded on t he Sour ce Document  Recor d.  The I nv est i gat or  wi l l  in di cate  t he pr i mary  r eason  
f or  d iscont i nuat i on by  sele ct i ng one of  t he boxes pr ov i ded on t he Ex it  eCRF . Comment s  can  
be added to  t he eCRF i f  necessar y .  
 
I f  a subj ect  i s d iscont i nued out si de of  a v i si t  win dow,  an Unschedu led Vi si t  eCRF must  a lso be  
comp let ed 
 
 
7 .5 Unschedule d Vi si t s  
 
An unschedul ed v i si t  i s def in ed as any  f o ll ow- up t hat  occurs  out sid e t he v i si t  wi ndow of  t he  
schedul ed v i si t .  A v i si t  i s al so cla ssi f i ed as unschedul ed i f  t he subj ect  i s seen a second t i me  
wi t hi n t he schedul ed v i si t  win dow.  
 
I nv est i gat ors  shoul d t r y  as f ar  as possi bl e to  schedul e f o ll ow- up v i si t s  wi t hi n t he wi ndow.  I f  t h is  
i s not  poss i b le,  and t he v is i t  f a l ls out s i de t he wi ndow,  t he v i si t  wi l l  be an unschedul ed v i si t ,  
unl ess i t  has been agr eed wi th  VCR t hat  i t  can be conside r ed a schedul ed v i s i t .  
 
A lt er nat i v el y ,  t he I nv est i gat or  migh t  j udge t hat  a f o ll ow- up v i si t  i s i n t he best  in t er est  of  t he  
subj ect  and schedul e t wo v i s i t s  wi t hi n t he same wi ndow,  e. g.  f o l low- up of  an adv er se ev ent .  
Unschedule d v i si t s  are  a lso made av ai l abl e any t i me at  t he subj ect ’ s r equest .  
 
Unschedule d vi si t s  wi l l  be r ecor ded on t he Unschedul ed Vi si t  eCRF . Al l  v ar ia ble s l i st ed on t he  
f or ms must  be comp let ed unle ss t he  subj ect  exhi bi t s  a condi t i on  that  pr ohi b it s  t he comp let i on  
of  a f u ll  v i si t .  I f  t h is i s t he case,  a wr i t t en exp lanat io n i s r equ ir ed i n t he comment s  sect i on ( e. g.  
not  wear i ng len ses due t o di scom for t ) .  
 
Pr esent in g VA,  sl i t  la mp v ar ia ble s and sy mpt oms in clu din g dr y ness must  a lway s be comp let ed  
and t he r eason f or  t he v i si t  and any  act i ons t aken must  be in di cat ed on t he f or ms.  
 
 
7 .6 S it e Tr a ini ng and V is i t s  
 
The st udy  in i t i at i on wi l l  t ake p lace v i a on- l in e t r ai ni ng module s and a phone cal l .  
 
The sponsor  or  VCR may  choose to  i n it ia t e an on- si t e v i s i t  as deemed appr opr i at e.  I f  t h is  
occur s,  VCR wi l l  ema il  pr i or  to  t he v i si t  to  ar r ange a conv enien t  t i me.  I nt er i m and clo se- out  
mon it or in g v i si t s  wi l l  be document ed i n t he Mon it or i ng P lan whi ch i s a separ ate  document .  
 
 
8 ADVERSE EVENTS 
 
An Adv er se Ev ent  ( AE)  i s def ine d as any  unf av or abl e or  unin t ended sig n ( i ncl ud ing an abnor mal  
f ind i ng) ,  sy mpt om or  d isease t empor ar i l y  associ at ed wi th  t he use of  a st udy  dev i ce whet her  or  
not  r el at ed to  t he st udy  dev i ce.  Al l  ocula r  AEs and r e lat ed ( to  t he st udy  devi ce and/ or  to  t he  
st udy  pr ocedur es)  non- ocul ar  AEs,  wi l l  be mon it or ed and r epor t ed on t hr oughout  t he st udy .  
 
Tr ansien t  sy mpt oms such as end- of - day  dr y ness,  le ns awar eness,  i t chin g or  bur n ing or  ot her  
d iscom for t  may  occur  wi th  cont act  l ens wear  and may  occasiona l l y  r educe wear i ng t i me.  These  
are  not  r epor t ed as adv er se ev ent s  unle ss i n t he i nv est i gat or ’ s opin i on t hey  are  unexpect ed i n  
nat ur e,  sev ere  or  hav e a hi gh r ate  of  occur r ence.  
 
Possi bl e ocu lar  AEs are  summar i z ed i n Tab le 3 bel ow.  
 
The In v est ig at or  wi l l  be r equ ir ed to  j udge whet her  or  not  an AE i s dev i ce- r e lat ed.  Re- occur r in g  
dev i ce- r el at ed  ev ent s  f r om t he same subj ect  are  usual l y  t abula t ed as  separ at e ev ent s.  I n t he 
V I  S I  O N C A R E    R E S E A R C H 
Page 31 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
8 .2 Adv er se Ev ent  Repor t i ng 
 
On f i nd ing an AE t he I nv est i gat or  wi l l  comp lete  an Adv er se Ev ent  f orm  ( AE f or m)  i n EDC to  
capt ure  t he ev en t.  
 
The I nv est iga t or  must  not i f y  Vi si oncare  Resear ch of  t he AE,  so t hat  t hey  are  abl e to  pr ov id e  
adv i ce and suppor t  to  t he I nv est ig at or  on how to  pr oceed.  
 
The I nv est i gat or  must  do t h is by  pr ov i din g t he in f or mat i on on t he AE eCRF as soon as possib l e  
as and no la t er  t han:  
 
• 24 hours  f r om d iscov er y  i f  ev ent  i s Ser iou s or  Si gni f i cant  
 
• 5 wor kin g day s f r om d iscov er y  i f  ev ent  i s Non- Si gn if i cant  
 
Once t he f or m i s  sav ed,  an aut omat i c ema il  wi l l  be sent  to  VCR and t he Sponsor  to  not i f y  t hem  
of  t he ev ent .  I f  t he AE f orm  i n EDC cannot  be comp let ed on t he day  of  d iscov er y  of  t he AE,  
t hen t he Medi cal  Mon it or  must  be cont act ed to  not i f y  t hem of  t he AE.  
 
I f  appl i cable ,  VCR wi l l  adv is e t he I nv est ig at or  t o not i f y  t he I RB as per  t he I RB r equ ir ement s .  
VCR may  not i f y  t he I RB on behal f  of  t he I nv est ig at or .  
 
The In v est iga t or  must  not i f y  VCR i n wr i t i ng t hat  t he AE has been r epor t ed to  t he IR B.  
 
 
8 .3 Adv er se Ev ent  Document at i on 
 
I nv est i gat ors  are  r equi r ed t o document  and f o ll ow- up a ll  AEs.  
 
Al l  AEs must  document ed on an AE f orm  i n EDC upon ev ent  di scov er y .  For  al l  ocu lar  AEs,  
one AE f or m i s used per  ey e.  For  AEs  whi ch are  non- ocu lar  onl y  one AE f or m wi l l  need t o be  
comp let ed i n EDC per  AE.  
 
P rocedure :  
 
The In v est iga t or  has t he r es ponsi bi l i t y  t o:  
 
1 . Comp lete  as much in f or mat i on as poss i b le on t he AE f or m i n EDC upon ev ent  di sc ov er y .  
Th is in clu des:  
 
• A det ai l ed descr ip t i on of  t he AE and a di agnosi s,  i ncl ud ing a pr obabl e cause.  
• L ike l ihood of  t he AE bein g dev i ce- r el at ed 
• Lens l ot  and power  det ai l s ( i r r espect i v e of  whet her  l enses were  bein g worn  at  t i me of  
t he AE)  
 
2 . I nclu de i n t he pat i ent  not es det ai le d dr awi ngs t hat  det ai l  s iz e,  l ocat i on and dept h or  
phot ogr aphs ( i f  necessar y )  
 
3 . I f  ser iou s,  co ll ect  any  cont act  len ses wor n,  solu t ion s,  and t he l ens case used at  t he t i me.  
 
4 . Repor t  t he AE to  t he sponsor  ( v i a VCR ) and t he I RB wi t hi n t he speci f ie d t i me l ines ( see  
Adv er se Ev ent  Repor t i ng sect io n 8. 2) .  
 
5 . Fo ll ow st udy  subj ect  unt i l  r eso lut io n r ecor di ng al l  in f or mat i on on an unschedul ed v i si t  eCRF ,  
in cl udi ng VA,  sy mpt oms,  sl i t  la mp f ind i ngs,  r esol ut i on,  and per manent  sequel ae i f  any .  
 
6 . Comp lete  al l  r ema ini ng in fo r mat i on as r equ ir ed on t he AE r esol ut i on eCRF . I f  f ol l ow- up of  
t he AE i s  requi r ed,  t he r esolu t io n f orm  can onl y  be comp let ed when al l  AE f ol l ow- up v i si t s  
are  f in i shed.  The f ol l owi ng add it i onal  i nf or mat i on wi l l  al so be comp let ed   on t he AE  
r eso lut io n f or m:  
 
• Out come,  ocu lar  sequel ae i f  any  
V I  S I  O N C A R E    R E S E A R C H 
Page 32 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
• Whet her  t he pat i ent  i s di scont i nued f r om t he st udy  as a r esu lt  of  t he AE 
 
 
8 .4 Adv er se Ev ent  Fol l ow- up 
 
The I nv est iga t or  wi l l  conduct  f o l low- up examina t i ons unt i l  t he condi t ion :  
 
• Has r et ur ned to  pr e- ev ent  st at us,  
• I s  conside r ed st abi l i z ed 
• O r has been sat i sf act or i l y  exp lai ned.  
 
I f  t he subj ect  i s r ef er r ed f or  med ical  at t ent i on,  t hey  w i l l  be t r acked by  t he I nv est i gat or  unt i l  t he  
af or ement i oned condi t i ons are  met .  
Fo ll ow- up dat a wi l l  be col l ect ed on an unschedul ed v i si t  eCRF and on t he AE f orm  i n EDC .  
The In v est i gat or  shoul d use h is/ her  c l i ni cal  j udgement  as to  whet her  or  not  t he subj ect  r epor t i ng 
wi th  an AE shoul d cont i nue i n t he st udy .  
 
8 .4 .1 Dev i ce Def i c i ency  
 
A dev i ce def i cien cy  means  t he f ai lu re  of  t he dev i ce t o meet  i t s  per f or mance speci f i cat i on or  
ot her wi se per f orm  as in t ended.  A dev i ce def i c i ency  woul d be consi der ed r epor t abl e to  t he  
Sponsor  i f  consi der ed t o be l i kel y  to  cause or  cont r ib ut e to  a Ser i ous Adv er se Ev ent .  
 
The I nv est i gat or  wi l l  be r equ ir ed t o r epor t  al l  r epor t abl e dev i ce def i ci encie s to  t he VCR /Sponsor  
v i a t he appl i cabl e f orm  i n t he EDC sy st em.  
 
8 .4 .2 Sponsor  Saf et y  Respons i bi l i t ie s 
 
The sponsor  wi l l  ensure  t hat  al l  par t i cip at i ng I nv est i gat ors  are  pr ompt l y  i nf or med of  sign i f i cant  
new saf et y  in f or mat i on wi th  r espect  to  t he st udy  dev i ces as per  r egula t or y  r equi r ement s.  
 
To compl y  wi t h t h is,  t he sponsor  i s r esponsi bl e f or  pr ompt l y  adv i si ng ( i n wr i t in g,  v i a VCR ) al l  
In v est i gat ors  conduct i ng cl in i ca l  st udi es of  any  in c i dent s  of  ser iou s or  unexpect ed adv er se  
ev ent s/ unant i ci pat ed adv er se dev i ce ef f ect s  r epor t ed f or  t he dev i ces/ pr oduct s  i nvol v ed i n t hose  
st ud ies.  
 
 
8.5  St udy  Comp let i on 
 
The st udy  i s comp let ed when al l  subj ect s  hav e comp let ed t he f in al  v i si t  ( Vi si t  3 or  5 dependi ng  
on cont r ol  len s gr oup)  or  been di scont i nued,  and hav e been exi t ed f r om t he st udy .  
 
 
9 DATA MANAGEMENT 
 
 
9 .1 E lect r on ic Case Repor t  For ms/D ata  Col le ct io n 
 
The cl i ni cal  data  f or  t hi s st udy  wi l l  be ent er ed by  des i gnat ed st udy  si te  per sonnel  onto  el ect r oni c  
r epor t  f or ms ( eCRFs)  usin g t he e lect r on ic data  col l ect i on ( EDC ) sy st em Medr io .  
 
Medr i o i s comp l iant  wi t h al l  r e lev ant  aspect s  of  ICH / Good Cl in i cal  Pr act i ces and 21 CFR Par t  
11 ( Ele ct r oni c Recor ds & E lect r on ic S ignat ur es)  r egula t ion s.  
V I  S I  O N C A R E    R E S E A R C H 
Page 34 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
v .  Ov er al l  len s f i t  accept ance [ 0- 4] .  
 
 
10 .3 St at i st i cal  Consi der at i ons 
 
Al l  st at i st i cal  anal y ses wi l l  be per f or med us i ng t he SAS sof tw are  Ver si on 9.4  or  la t er  ( SAS  
I nst i t ut e,  Car y ,  NC ) . 
 
The f ina l  anal y si s wi l l  be comp let ed af t er  al l  subj ect s hav e been exi t ed f r om t he st udy ,  al l  
quer i es hav e been r esol v ed,  and t he dat abase has been l ocked.  
 
The ov er al l  t y pe I  er r or  r at e wi l l  be pr eser v ed at  5% . Al l  t est s  wi l l  be t wo- sid ed.  The pr i mar y  
hy pot hesi s must  be met  i n or der  to  sat i sf y  t he obj ect i ve of  t h is st udy .  
 
F rom t he i nser t i on and r emov al  t i mes t he av er age wear in g t i me wi l l  be ca lcula t ed.  I f  t he subj ect  
in di cat es t hat  l ens com for t  det er i or at es dur i ng wear ,  t he com for t ab le wear i ng t i me wi l l  be  
ca lcu lat ed f r om t he i nser t i on t i me and t he t i me t hat  l enses become uncomf or t able .  I f  t here  i s  
no det er i or at i on i n comf or t  t hen t he av er age wear in g t i me wi l l  be used      
     
 
Data  f r om unschedu led v i s i ts  wi l l  not  be i nclu ded i n t he anal y si s.  
 
Any  devia t ion s f r om t h is anal y si s pl an wi l l  be det ai l ed i n t he st udy  r epor t .  
 
 
10 .4 Anal y si s Popula t io n 
 
St at i st i cal  anal y ses wi l l  be conduct ed on al l  r andomi z ed subj ect s  who hav e success f u ll y  
comp let ed t he st udy  wi t hout  a pr ot ocol  dev i at io n t hat  i s r egar ded as i mpact i ng t he assess ment  
of  t he pr i mar y  hy pot hesi s ( as per  pr ot ocol ) .  M issi ng data  wi l l  be exc l uded f r om t he anal y si s  
and wi l l  not  be ext r apol at ed f r om t he co l lect ed dat a.  
 
 
10 .5 Descr ip t i v e St at i st i cs 
 
Descr ip t i v e st at i st i cs wi l l  be r epor t ed at  d ispens i ng and each f o ll ow- up v i si t .  Cont i nuous  
v ar i abl es wi l l  be summar i z ed usin g mean,  st andard  dev i at i on,  and r ange;  and cat egor i cal  data  
v ar i able s wi l l  be summar i z ed usi ng per cent  f r equenc y  d ist r i but io n,  mean,  and SD . Nomin al  
v ar i able s wi l l  be summar i z ed usi ng per cent ages.  
 
Summar ie s wi l l  be pr esent ed by  cont r ol  gr oup f or  each l ens t y pe.  
 
 
10 .6 Data  Pool in g 
 
Data  wi l l  be pool ed f r om mu lt ip l e st udy  si t es f or  t h is anal y si s,  t he basi s f or  poo l ing comes f r om  
t hr ee f act or s:  
 
• The st udy  si t es must  i mp lement  one common pr ot ocol .  
• VCR must  clo sel y  mon it or  st udy  si te  pr ot ocol  comp l iance.  
• The st udy  si t es must  use common data  co ll ect i on pr ocedur es.  
 
 
10 .7 Pr i mar y  St at i st i cal  Anal y si s 
 
Com for t  scor es at  t he f in al  f o l low- up v i si t  wi l l  be anal y sed usin g a mi xed l i near  mode l.  The  
model  wi l l  i ncl ude t he f ol l owin g f i xed ef f ect s:  len s t y pe,  cont r ol  gr oup,  si t e,  and t he in t er act i on  
of  len s  t y pe by  cont r ol  gr oup;  and subj ect  nest ed i n si t e as a  random ef f ect .  The l east - square  
means and t he ir  di f f er ences wi l l  be r epor t ed wi t h 95% conf iden ce i nt er v a ls f or  each len s t y pe 
V I  S I  O N C A R E    R E S E A R C H 
Page 35 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
by  cont r ol  gr oup.   Conclu sion s wi l l  be dr awn f r om t he 95% conf iden ce i nt er v al  of  t he l east -  
square  mean d if f er ences.  
 
 
10 .8 Secondar y  St at i st i cal  Anal y si s 
 
The secondar y  v ar i able s wi l l  be  anal y sed usin g mi xed l i near  mode ls.  The model s  w i l l  i nclu de  
t he f ol l owin g f i xed ef f ect s:  len s t y pe,  cont r ol  gr oup,  s it e,  and t he in t er act i on of  l ens t y pe by  
cont r ol  gr oup;  and subj ect  nest ed i n si t e as a r andom ef f ect .  The lea st - square  means and t hei r  
di f f er ences wi l l  be r epor t ed wi t h 95% conf i dence i nt er va ls f or  each l ens t y pe by  cont r ol  gr oup.  
Conclu sion s wi l l  be dr awn f r om t he 95% conf id ence in t er v al  of  t he l eas t - square  mean  
d if f er ences.  
 
 
10 .9 Addi t i onal  St at i st i cal  Anal y si s 
 
O ther  se lect ed v ar ia ble s may  be anal y sed us i ng appr opr ia t e st at i st i cal  met hods .   A P- v al ue  
le ss t han or  equal  t o 0. 050 wi l l  be r egar ded as st at i st i ca ll y  s i gni f i cant .  
 
 
10 .10 I nt er i m Anal y si s 
 
There  are  no pl anned in t er i m anal y ses f or  t h is st udy .  
 
 
11 GENERAL STUDY MANAGEMENT 
 
 
11 .1 Re lev ant  St andar ds 
 
Th is pr ot ocol  has been deve loped i n accor dance wi t h t he f o ll owi ng:  
 
• I SO 14155- 1: 2011 Cl i n ical  I nv est ig at i on of  Med ical  Devi ces f or  Human Subj ect s  
 
• I SO 11980: 2012 Cont act  Lenses and Cont act  Lens Care  Pr oduct s  – Gu idance fo r  Cl i ni cal  
In v est i gat i ons.  
 
• ICH  Har moni z ed Tr ipa r t i te  Gu idel i ne f or  Good Cl i ni cal  Pr act i ce 
 
• Decla r at i on of  He lsin ki  
 
The st udy  wi l l  a lso be car r i ed out  i n accor dance wi t h t he VCR Qual i t y  Management  Sy st em  
( I SO 9001: 2015)  and al l  th e appl i cabl e l ocal  guid el i nes.  
 
 
11 .2 Et hi cs Rev i ew 
 
The st udy  pr ot ocol ,  Par t i ci pant  I nf or mat i on Sheet  and I nf or med Consent  Form  and al l  ot her  
r equ ir ed document s  wi l l  be submi t t ed to  St er l i ng I RB f or  each si t e.  A f av or abl e opi n ion wi l l  be  
r ece iv ed pr io r  t o under t aki ng t he st udy .  
 
I f  sign i f i cant  pr ot ocol  changes whi ch r equ ire  t he pr epar at i on of  an amendment  are  necessar y ,  
wr i t t en I RB appr ov al  wi l l  be obt ai ned pr io r  to  i mp lement at i on.  
 
 
11 .3 Pr ot ocol  Dev ia t ion s 
 
The I nv est i gat ors  wi l l  not  dev ia te  f r om t he pr ot ocol  wi t hout  wr i t t en appr ov al  f r om t he I RB and  
VCR . 
V I  S I  O N C A R E    R E S E A R C H 
Page 36 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
In  med ical  emer gencie s,  In v est i gat ors  wi l l  use t he ir  j udgement  and r emov e t he subj ect  f r om  
i mmed iate  haz ar d.   Any  s i gn if i cant  changes or  dev i at i ons i n t he pr ot ocol  wi l l  be th e subj ect  of  
a pr ot ocol  amendment  and must  be pr e- appr ov ed by  t he IR B.  
 
I f  an unexpect ed dev ia t i on f r om t he pr ot ocol  occurs  t he I nv est i gat or  must  not i f y  t he VCR  
i mmed iat el y  and t he dev i at i on f r om t he pr ot ocol  wi l l  be r epor t ed on a Pr ot ocol  Dev i at i on f or m  
i n EDC and appr opr i ate  act io n t aken.  
 
 
11 .4 Pr emat ure  Ter mina t i on of  t he St udy  
 
The sponsor  r eser v es t he r igh t  to  t er mina te  t he st udy  at  any  t i me f or  any  r eason in c l udi ng  
adv er se ef f ect s.  I f  i t  i s det er mine d t hat  an unant i cip at ed adv er se dev i ce ef f ect  pr esent s  an  
unr easonabl e r i sk,  t hen t he ent i re  i nv est i gat i on or  par t  of  t he i nv est i gat io n pr esent i ng t he r i s k  
sha ll  be t er mina t ed as soon as possi bl e.  A wr i t t en st at ement  f u ll y  document i ng t he r easons f or  
such t er mina t i on wi l l  be pr ov i ded to  t he I RB.  
 
 
11 .5 Sour ce Document at i on 
 
Un less ot her wi se document ed,  t he eCRFs wi l l  be consi der ed t he sour ce document .  The  
sponsor  or  sponsor ’ s r epr esent at i v es wi l l  be aut hor i z ed to  gai n access to  t he sour ce  
document at i on f or  t he pur poses of  mon it or i ng and audi t i ng t he st udy  ( See Sect i ons 11. 6,  11. 7) .  
 
The Sour ce Document  Record  must  be comp let ed t o compl y  wi t h GCP gui del i nes.  I t  i s a  
per manent  r ecord  wi t hi n th e pat i ent ’ s char t / not es t hat  document s  t he subj ect ’ s i nv ol v ement  i n  
a cl i n ical  r esear ch st udy .  
 
Cont ent s  of  t he sour ce document  r ecor d:  
• St udy  number  
• Subj ect  ID  
• Conf i r mat i on t hat  subj ect  met  el i gi bi l i t y  cr i t er i a 
• Conf i r mat i on t hat  subj ect  s igned t he in f or med consent  
• Conf i r mat i on t hat  subj ect  r ece iv ed a sig ned and dat ed copy  of  in f or med consent  
• Date  enr ol l ed 
• Det ai l s of  l enses worn  on st udy  
• Gener al  not es  
• Adv er se ev ent s  
• Repor t abl e Pr ot ocol  dev ia t i ons 
• Exi t  date  
• Whet her  subj ect  comp let ed t he st udy  or  di scont i nued 
• I nv est i gat or ’ s s i gnat ure  
 
The Sour ce Document  Record  wi l l  be comp let ed f or  each subj ect  upon enr o lment  and t hen  
updat ed when r equ ir ed,  e.g .  when subj ect  ex i t s  t he stud y .  
 
 
11 .6 Moni t or i ng 
 
I nv est i gat i onal  si te  mon it or i ng wi l l  be per f or med by  a qual i f ie d st udy  mon it or  i dent i f ie d by  t he  
sponsor  or  VCR . On- si te  v i si t s  wi l l  be comp let ed at  each si te .   The f r equency  and pr ocedure  
of  t he mon it or i ng v i si t s  wi l l  be document ed i n t he Mon it or i ng P lan wh ich i s i n a separ ate  
documen t.  The I nv est iga to r  wi l l  al l ow t he st udy  mon it or  and sponsor  r epr esent at iv es or  I RB to  
obser v e pr ocedur es and i nspect  st udy  r ecor ds and subj ect s’  med ical  r ecor ds t hr oughout  t he  
st udy  t o v er i f y  pr ot ocol  comp l iance,  case r epor t  comp let eness,  and i nv est i gat i onal  mat er i al  
account abi l i t y .  Shoul d t he I nv est i gat or  be f ound to  be non- comp l iant  and unwi l l i ng or  unabl e  
to  conv er t  noncomp l iant  pr act i ces,  VCR i n consul t at i on wi t h t he sponsor  wi l l  te r mina te  t he  
In v est i gat or ’ s r ol e i n t he i nvest i gat i on and t he I RB wi l l  be not i f i ed.  
V I  S I  O N C A R E    R E S E A R C H 
Page 37 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
11 .7 Audi t s  
 
The I nv est i gat or  shal l  per mi t  VCR , t he sponsor  and t he I RB to  i nspect  i t s  f ac i l i t ie s,  equi pment ,  
and st udy - r ela t ed r ecor ds,  data  and ot her  document s  upon r easonabl e not i ce.  In  addi t i on,  t he  
IRB  may  conduct  such i nspect i ons as t hey  deem necessar y  at  any  t i me whet her  or  not  
adv anced not i ce i s gi v en by  t hem.  The I nv est i gat or  agr ees to  not i f y  t he sponsor  or  VCR wi t hi n  
24 hours  ( or  as soon as r easonabl y  pr act i cable )  of  t he st ar t  of  any  unannounced i nspect i on by  
t he I RB or  of  t he r ece ipt  f r om t he IRB  of  a not i ce of  in s pect i on whet her  gi v en i n wr i t i ng or  or al l y .  
I f  such not i ce i s i n wr i t ing ,  a copy  wi t h any  at t achment s  t her eto  shal l  be pr ov i ded t o VCR or  t he  
sponsor .  
 
 
11 .8 Recor ds Ret ent io n 
 
Accor d ing t o t he ICH  GCP gui del i nes t he essent i al  document s  shou ld be r et ain ed unt i l  at  l east  
two  y ears  af t er  t he l ast  appr ov al  of  a mar ket i ng appl i cat i on i n an I CH r egi on and unt i l  t here  are  
no pendi ng or  cont emp late d mar ket i ng appl i cat i ons i n an ICH  r egio n or  at  lea st  t wo y ears  hav e  
e lapsed sin ce t he f or mal  disc ont i nuat i on of  cl i ni cal  deve lopment  of  t he in v est iga t i onal  pr oduct .  
I t  i s t he r esponsi bi l i t y  of  t he sponsor  t o i nf or m t he I nv est i gat or / i nst i t ut i on as to  when t hese  
document s  no lo nger  need to  be r et ai ned.  The st udy  l ens mat er ia l  i s al r eady  on t he mar ket  
and t her ef ore  t he st udy  document s  shou ld be kept  f or  a min i mum of  t wo y ears  af t er  t he end of  
t he st udy .  As t he c l i ni cal  r esear ch or gani z at i on super v is in g t he st udy ,  VCR wi l l  al so r et a in t he  
wr i t t en r ecor ds f or  t he same per i od of  t i me.  Fol l owi ng such r et ent i on per i od,  t he I nv est i gat or  
or  t he Cl i ni cal  Si te  shal l  de li v er  t o t he sponsor  al l  such Resear ch Resul t s,  unl ess ot herw i se  
in st r uct ed i n wr i t in g by  t he sponsor .  Not wi t hst andi ng t he f or egoin g,  al l  in f or mat i on pr ov i ded by  
or  wi t h r espect  t o subj ect s  i n t he St udy  wi l l  be f ur n ished by  I nv est i gat or  and Cl in i cal  Si te  wi t hout  
pat i ent  names.  
 
 
11 .9 Conf id ent i al i t y  and Publ i cat io n 
 
Th is  st udy  i s  conf id ent i al  i n nat ur e.  The I nv est i gat or  shal l  make no publ i c  st at ement ,  whet her  
i n wr i t t en,  or al  or  ele ct r oni c f or m,  r e lat i ng t o t he VCR , t he Sponsor ,  t he subst ances,  mat er ia l s ,  
pr oduct s  and dev i ces bei ng i nv est i gat ed or  t he St udy  i t se lf  wi t hout  obt ai ni ng t he pr io r  wr i t t en  
consent  of  t he VCR or  t he Sponsor .  
 
Al l  in f or mat i on gat her ed dur in g t hi s st udy  i s pr opr i et ar y  and shou ld be made av ai l abl e onl y  t o  
t hose di r ect l y  i nv ol v ed i n th e st udy  who have a need to  know.  
 
Aut hor i z ed r eci pie nt s  of  t hi s data  in c l ude:  
 
▪ I nv est i gat or  and co- i nv est i gat or ( s)  
▪ O ther  al l i ed heal th  care  per sonnel  necessar y  f or  t he conduct  of  t he st udy  
▪ IRB  per sonnel  
▪ Sponsor  r epr esent at i v es 
▪ Cont r act  Resear ch O rganiz at i on 
▪ Desig nat ed st udy  mon it or  
▪ Desig nat ed med ical  mon it or  
▪ FDA or  ot her  gov er nment  r egula t or y  agencie s 
 
Al l  above per sonnel  who are  pr ov i ded wi th  data  concer n ing t hi s st udy  wi l l  be in f or med of  i t s  
conf iden t i al  and  pr opr ie t ar y  nat ur e.  Rel ease of  t h is data  ( t hr ough  pr esent at i on,  publ i cat i on or  
ot her  wr i t t en or  or al  commun icat ion )  to  ot her  t han t he abov e l i st ed per sonnel  r equi r es t he pr io r  
wr i t t en per mi ssio n f r om t he st udy  Sponsor .  St udy  i nv est i gat ors  and al l  of f i ce per sonnel  are  
pr ohi b it ed f r om ac knowl edgin g par t i cipa t i on i n t he st udy  to  i ndiv id ua ls and or gani z at ion s except  
t hose l i st ed abov e.  Th is i nclude s sale s r epr esent at i v es and ot her  depar t ment s  or  subsi dia r i es  
of  t he sponsor  wi t hout  t he d ir ect  wr i t t en per mi ssio n of  t he sponsor .  
V I  S I  O N C A R E    R E S E A R C H 
Page 38 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
The st udy  wi l l  conf or m t o t he r equ ir ement s  of  t he Heal th  I nf or mat i on Por t abi l i t y  and  
Account abi l i t y  Act  (H I PAA) .  By  sig ni ng t he aut hor i z at i on to  use and di sclo se pr ot ect ed hea lt h  
in f or mat i on t he subj ect  aut hor i z es t he sponsor  and t he sponsor ’ s r epr esent at i ves ( VCR ) to  
access t he ir  opt omet r i c cl i ni cal  r ecor ds.  Th is aut hor i z at i on wi l l  expi re  50 y ears  f r om t he date  
t he subj ect  s i gns.  Subj ect s  wi l l  have t he r i ght  t o r ev er se t hi s aut hor i z at i on at  any  t i me.  
 
Al l  pat i ent  i nf or mat i on wi l l  hav e t he pat i ent  name ( or  any  in f or mat i on t hat  can id ent i f y  t he pat i ent  
apar t  f r om t he mob i le phone number )  r emove d bef ore  le av i ng t he Pr in cip al  I nv est i gat or ’ s s i t e.  
 
In  accor dance wi t h t he VCR Conf id ent i al i t y  Pol i cy ,  th e dat a,  i nf or mat i on,  and r epor t s  ar i si ng  
f r om t h is pr oj ect  are  t he pr oper t y  of  t he sponsor  company .  By  si gni ng t he I nf or med Consent  
For m t he subj ect  a lso under st ands t hat  t he ir  dat a wi l l  be sent  to  VCR i n t he UK and t he sponsor  
i n t he US.  VCR wi l l  not  r el ease to  a t hi rd  par t y  any  in f or mat i on ar i s in g f r om t h is s t udy  unle ss  
r equ ir ed to  do  so by  a le gal  or  r egu lat or y  body .  The  el ect r on ic r ecor ds wi l l  al so  be hand led i n  
accor dance wi th  Heal th  I nf or mat i on Por t abi l i t y  and Account abi l i t y  Act  (H I PAA) .  
 
The st udy  wi l l  be r egi st er ed on t he websi t e www. cl i n ical t r i al s. gov .  
V I  S I  O N C A R E    R E S E A R C H 
Page 39 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
12 REFERENCES 
 
1 . Ef r on N , Ni cho ls JJ,  Woods  CA,  Mor gan PB.  Tr ends i n US Cont act  Lens Pr escr ib i ng 2002  
to  2014.  Opt om Vi s Sci  2015;  92: 758- 67.  
 
2 . Mor gan PB et  al .  I nt er nat i onal  Cont act  Lens Pr escr ib i ng i n 2018 Cont  Lens Spect r um,  
Vol ume:  34( 1) :  26- 32.  
 
3 . FDA 510k Summar y :  K160803 Av a ir a Vi t al i t y  ( f anf i l c on A)  Sof t  ( hy dr ophi l i c)  Cont act  
Lenses.  
 
4 . Sz cz ot ka- Fl y nn LB,  Debanne S,  Benet z  BA,  Wi l son T,  Br ennan N . Dai l y  Wear  Cont act  
Lenses manuf act ur ed i n Et af i l con A are  nonin f er io r  to  t wo si l i cone hy dr ogel  l ens t y pes wi th  
r espect  to  hy poxi c st r ess.  Ey e Cont act  Lens.  2018;  44: 190- 199.  
 
5 . Lebow KA,  Schachet  JL.  Ev alua t i on of  cor neal  st ai ni ng and pat i ent  pr ef er ence wi th  use of  
t hr ee mu lt i - pur pose so lut i ons and t wo br ands of  sof t  cont act  l enses.  Ey e Cont act  Lens.  
2003;  29: 213- 20.  
 
6 . Young G , Schni der  C,  Hunt  C,  Ef r on S.  Cor neal  t opogr aphy  and sof t  cont act  len s f i t .  Opt om  
V is Sci .  2010;  87( 5) : 358- 66.  
 
7 . Maï ssa C , Gui l l on M,  Gar o fa lo RJ.  Cont act  l ens- in duced ci r cuml i mbal  st a ini ng i n si l i cone  
hy dr ogel  cont act  len ses worn  on a dai l y  wear  basi s.  Ey e Cont act  Lens.  2012 Jan; 38( 1) : 16-  
26.  
 
8 . Ber nt sen DA,  Mer chea MM,  Ri chdal e K,  Mack CJ,  Bar r  JT.  Highe r - or der  aber r at i ons when  
wear i ng sphere  and t or i c sof t  cont act  l enses.  Opt om V is Sci .  2009;  786: 115- 22.  
 
9 . Bar th  B,  Al v es MR , Kara - José N . [ Vi sual  per f or mance i n my op ic cor r ect i on wi th  spect acle s  
and sof t  cont act  l enses] .  Ar q Br as Of t a lmo l.  2008; 71: 90- 6.  Por t uguese.  
 
10 . Ef r on S,  Ef r on N , Mor gan PB.  Opt i cal  and v i sual  per f or mance of  aspher i c sof t  cont act  
len ses.  Opt om V is Sci .  2008; 85: 201- 10.  
 
11 . Ri chdal e K,  Ber nt sen DA,  Mack CJ,  Mer chea MM,  Bar r  JT.  V isual  acu it y  wi t h spher i cal  and  
t or i c sof t  cont act  len ses i n l ow-  to  moder at e- ast i gmat i c  ey es.  Opt om V is Sci .  2007; 84: 969-  
75.  
 
12 . Bucci  FA Jr ,  My ers  PJ,  Evans RE,  Tanner  JB,  Moody  KJ,  Lopat y nsky  MO . Cl i ni cal  and  
ov er ni ght  cor neal  swel l  compar i son of  t he 1- Day  Acuv ue len s v er sus t he Medal i st ,  Sur ev ue,  
B iomed ics,  and Acuv ue le nses.  CLAO J.  1997; 23: 103- 12.  
V I  S I  O N C A R E    R E S E A R C H 
Page 40 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019  
  
 
APPENDI X A 
 
 
 
 
     
Page 47 o f 48 PRO AVAR- 402  Ve rs i on  1  22MAR2019 V I  S I  O N C A R E    R E S E A R C H 
M E A S U R E M E N T   I  N S T R U C T I  O N S  
  
   
 
 
        
 
                     
                    
       
 
                
                 
 
   
 
                  
               
 
   